Literature DB >> 11449502

Control of urinary risk factors of stones by betulin and lupeol in experimental hyperoxaluria.

L Vidya1, P Varalakshmi.   

Abstract

Urolithiasis, the process of formation of stones in the kidney and the urinary tract, is the major clinical manifestation of hyperoxaluria. Crystal deposition, as indicated by increased stone-forming constituents in urine, such as calcium, oxalate and uric acid, and decreased concentration of inhibitors, such as magnesium and glycosaminoglycans, was observed in pyridoxine-deficient hyperoxaluric rats. Renal tubular damage was indicated by increased excretion of enzymes such as alkaline phosphatase, lactate dehydrogenase, gamma-glutamyl transferase, beta-glucuronidase and N-acetyl glucosaminidase. Fibrinolytic activity was found to be reduced. Administration of pentacyclic triterpenes such as lupeol and its structural analogue betulin to hyperoxaluric rats minimised the tubular damage and reduced the markers of crystal deposition in the kidneys. In this connection, lupeol was found to be more effective than betulin.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11449502     DOI: 10.1016/s0367-326x(00)00192-1

Source DB:  PubMed          Journal:  Fitoterapia        ISSN: 0367-326X            Impact factor:   2.882


  4 in total

1.  Effect of extract of Phyllanthus niruri on crystal deposition in experimental urolithiasis.

Authors:  Marcio E Barros; Roberta Lima; Lucildes P Mercuri; Jivaldo R Matos; Nestor Schor; Mirian A Boim
Journal:  Urol Res       Date:  2006-12

2.  Effect of Costus igneus stem extract on calcium oxalate urolithiasis in albino rats.

Authors:  K Manjula; K Rajendran; T Eevera; S Kumaran
Journal:  Urol Res       Date:  2012-10

3.  Prospective randomized clinical trial comparing phytotherapy with potassium citrate in management of minimal burden (≤8 mm) nephrolithiasis.

Authors:  Iqbal Singh; Ishu Bishnoi; Vivek Agarwal; Shuchi Bhatt
Journal:  Urol Ann       Date:  2011-05

Review 4.  Recent advances in understanding and managing urolithiasis.

Authors:  Walter L Strohmaier
Journal:  F1000Res       Date:  2016-11-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.